Recently, I was approached by a colleague who had seen a patient with type 1 diabetes using a glucagon-like peptide-1 receptor agonist in combination with basal bolus insulin to manage their glucose levels.
Parliament is quiet, our attachment to the frenetic news cycle is unshackled and, for a few precious weeks, the yoyoing of outrage and frustration becomes a distant call of the lake loon.
